DiaSorin Italia S.p.A. UK Branch, Central Rd, Dartford DA1 5LR, UK www.diasorin.com Tel. +44 1322 317949

(E 0123

Changes: - Deletions: -

LIAISON® XL MUICX Control HBsAg (REF 317251)

1. INTENDED PURPOSE

The LIAISON® XL MUREX Control HBsAg (negative and positive) are intended for use as assayed quality control samples to monitor the performance and reliability of the LIAISON® XL MUREX HBsAg assay. The performance characteristics of LIAISON® XL MUREX HBsAg controls have not been established for any other assays or instrument platforms different from LIAISON® XL.

The certificate of analysis bar code gives, in the relevant area, specific information on the lot of controls and should be read by the hand-held bar code scanner of the LIAISON® XL Analyzer prior to loading the control vials on board. For details, refer to the analyzer operator's manual.

2. MATERIAL PROVIDED

Negative control (2 x 4.0 mL)	CONTROL -	Human plasma non-reactive for hepatitis B surface antigen, 0.2% ProClin™ 300, preservatives.
Positive control (2 x 4.0 mL)	CONTROL]+	Human serum reactive for hepatitis B surface antigen, 0.2% ProClin™ 300, preservatives.

All reagents are supplied ready to use. The range of concentrations of each control is reported on the certificate of analysis and indicates the limits established by DiaSorin for control values that can be obtained in reliable ass ay runs. Each laboratory is responsible for adopting different limits to meet individual requirements.

3. WARNINGS AND PRECAUTIONS

- For in vitro diagnostic use.
- For Laboratory Professional Use Only.
- Controls are not kit lot specific and may be safely interchanged even with different reagent integral lots.
- All materials used to produce the components provided in this kit have been tested for the presence of HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 and were found to be non-reactive, except for the positive control, which is reactive for HBsAg. The hepatitis B surface antigen has been heat treated (60°C for 10 hours) during the manufacturing process. Nevertheless, complete inactivation should not be assumed.
 - However, as no test method can offer absolute assurance that pathogens are absent, all specimens of human origin should be considered potentially infectious and handled with care.
- Observe the normal precautions required for handling all laboratory reagents.
- Disposal of all waste material should be performed in accordance with local guidelines.
- Visually inspect the vials for leakage. If the vials are found to be leaking, the local customer service should be notified immediately.

4. SAFETY PRECAUTIONS

Do not eat, drink, smoke or apply cosmetics in the assay laboratory. Do not pipette by mouth.

Avoid direct contact with potentially infected material by wearing laboratory clothing, protective goggles and disposable gloves. Wash hands thoroughly at the end of each assay.

Avoid splashing or forming an aerosol. All drops of biological reagent must be removed with a sodium hypochlorite solution with 0.5% active chlorine, and the means used must be treated as infected waste.

All samples and reagents containing biological materials used for the assay must be considered as potentially able to transmit infectious agents. Waste must be handled with care and disposed of in compliance with the laboratory guidelines and with the statutory provisions in force in each Country.

Any materials for reuse must be appropriately sterilized in compliance with the local laws and guidelines. Check the effectiveness of the sterilization/decontamination cycle.

Do not use kits or components beyond the expiration date given on the label.

Pursuant to EC Regulation 1272/2008 (CLP) hazardous reagents are classified and labeled as follows:

REAGENTS:	[CONTROL]-, [CONTROL]+]
CLASSIFICATION:	Skin sens. 1A H317 Aquatic chronic 3 H412
SIGNAL WORD:	Warning
SYMBOLS / PICTOGRAMS:	<u>(1)</u>
	GHS07 Exclamation mark
HAZARD STATEMENTS:	H317 May cause an allergic skin reaction. H412 Harmful to aquatic life with long lasting effects.
PRECAUTIONARY STATEMENTS:	P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P280 Wear protective gloves/protective clothing/eye protection/face protection. P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P362+P364 Take off all contaminated clothing and wash it before reuse P273 Avoid release to the environment.
CONTAINS: (only substances prescribed pursuant to Article 18 of EC Regulation 1272/2008).	Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H -isothiazol-3-one [EC no. 220-239-6] (3:1). (ProClin™ 300).

For additional information see Safety Data Sheets available on www.diasorin.com.

5. STORAGE AND STABILITY

Upon receipt, the controls must be stored at 2-8°C in an upright position to prevent adherence of the solution to the vial cap. Do not freeze. When controls are stored sealed and kept upright, they are stable at 2-8°C up to the expiry date. Once opened, controls are stable for twelve (12) weeks when properly stored at 2-8°C between two successive uses. Avoid bacterial contamination of controls. The controls should not be used past the expiry date indicated on the vial labels.

6. PREPARATION OF REAGENTS

- Place the control vials on a suitable rack on the analyzer. Each control vial allows at least 20 tests to be performed.
- The minimum volume required is 550 μL (150 μL control + 400 μL dead volume).
- At the time of use, equilibrate controls to room temperature (20-25°C) before opening the vials and keep them on board the instrument only for the amount of time required for quality control testing.
- After use, stopper the vials promptly and store them at 2-8°C in an upright position.
- During handling, use appropriate precautions to avoid bacterial contamination of controls.

7. HANDLING

For proper handling, please refer to the LIAISON® XL Analyzer operator's manual.

8. TARGET VALUES

The target values and ranges of HBsAg concentrations in the controls are printed on the certificate of analysis. They have been established after taking into account run variability with respect to the stored master curve, in order to guarantee accuracy of analytical results and to obtain indications on stability or deterioration of reagents. If controls values lie repeatedly outside the expected ranges, the test has most probably been performed incorrectly.

Summary of safety and performance is available on EUDAMED.

For EU only: please be aware that any serious incident that has occurred in relation to this IVD medical device shall be reported to DiaSorin Italia S.p.A. UK Branch and the Competent Authority of the EU Member State in which the user and/or the patient is established.

EN-C01317251GB, 01-2022-11



DiaSorin Italia S.p.A. Via Crescentino snc 13040 Saluggia (VC) Italy